Lavoltidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lavoltidine
DrugBank Accession Number
DB12884
Background

Lavoltidine has been used in trials studying the diagnostic of Reflux, Gastroesophageal and Gastroesophageal Reflux Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 359.474
Monoisotopic: 359.232125194
Chemical Formula
C19H29N5O2
Synonyms
  • lavoltidina
  • Lavoltidine
  • Loxtidina
External IDs
  • AH 23844
  • AH-23844

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmphetamineAmphetamine may decrease the sedative and stimulatory activities of Lavoltidine.
AmprenavirLavoltidine can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsunaprevirLavoltidine can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AtazanavirLavoltidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
BenzphetamineBenzphetamine may decrease the sedative and stimulatory activities of Lavoltidine.
Benzylpenicilloyl polylysineLavoltidine may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Lavoltidine.
BifonazoleLavoltidine can cause a decrease in the absorption of Bifonazole resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Lavoltidine.
BosutinibLavoltidine can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Phenylmethylamines / Phenoxy compounds / Phenol ethers / Benzylamines / Secondary alkylarylamines / Aralkylamines / Alkyl aryl ethers / Triazoles / Heteroaromatic compounds / Trialkylamines
show 5 more
Substituents
1,2,4-triazole / Alcohol / Alkyl aryl ether / Amine / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
piperidines, aromatic ether, primary alcohol, triazoles (CHEBI:6550)
Affected organisms
Not Available

Chemical Identifiers

UNII
X16K5179V5
CAS number
76956-02-0
InChI Key
VTLNPNNUIJHJQB-UHFFFAOYSA-N
InChI
InChI=1S/C19H29N5O2/c1-23-19(21-18(15-25)22-23)20-9-6-12-26-17-8-5-7-16(13-17)14-24-10-3-2-4-11-24/h5,7-8,13,25H,2-4,6,9-12,14-15H2,1H3,(H,20,21,22)
IUPAC Name
{1-methyl-5-[(3-{3-[(piperidin-1-yl)methyl]phenoxy}propyl)amino]-1H-1,2,4-triazol-3-yl}methanol
SMILES
CN1N=C(CO)N=C1NCCCOC1=CC=CC(CN2CCCCC2)=C1

References

General References
Not Available
KEGG Compound
C11805
PubChem Compound
55473
PubChem Substance
347829039
ChemSpider
50093
ChEBI
6550
ChEMBL
CHEMBL2110857
ZINC
ZINC000001532377
Wikipedia
Lavoltidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedDiagnosticGastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux1
1CompletedDiagnosticGastro-esophageal Reflux Disease (GERD) / Gastroesophageal Reflux1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.291 mg/mLALOGPS
logP2.94ALOGPS
logP2.03ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)13.45ChemAxon
pKa (Strongest Basic)8.74ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area75.44 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity116.23 m3·mol-1ChemAxon
Polarizability41.31 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 00:59 / Updated on February 21, 2021 18:54